360biolabs’ Decade of Enabling Future Medicines: The 10 Series
360biolabs' 10th anniversary
The 10 Series: A decade of enabling future medicines
Ten years ago, 360biolabs was founded with a bold vision, to build world-class bioanalytical expertise supported by the rigorous quality systems needed to advance clinical research. Today, that vision stands as a global standard of excellence. As we celebrate our 10th anniversary, we take pride in the partnerships, innovations, and scientific breakthroughs that have propelled us from a pioneering Melbourne startup to a trusted leader in the industry.
From Industry to Innovation
The mission of 360biolabs is to provide a diverse range of bioanalytical solutions to our clients, aiming to boost the success of the biotechnology and pharmaceutical industries. Since 2015, our laboratories in Australia have been consistently growing to cater to the requirements of our clients. Expanding our services and locations by becoming part of the global BioAgilytix team, we have been able to build the global clinical trial sector and maintain partnerships with clients as they progress into Phase 2 studies beyond Australia. Our company is committed to ongoing enhancement to align with the advancements made by our biotechnology partners.
From Melbourne Roots to Global Reach
2015 – 2017
Diversifying Clinical Trials in Australia
Our story began in 2015 at the prestigious Burnet Institute in Melbourne. With expertise in immunology and virology, we set out to expand the Australian clinical trials landscape by attracting a wider range of therapeutic areas and modalities with our diverse assay solutions.Growth came quickly. By 2016, we expanded into molecular biology, and by 2017, we added small molecule bioanalytical chemistry to our repertoire to become a one stop shop for all bioanalytical requirements. This early diversification ensured that we could support our partners across a vast range of therapeutic areas.
“In the early years, we were a small team working together with a clear purpose and sense of responsibility. Many of our clients were conducting their first clinical trial in Australia so they needed more than a bioanalytical laboratory, they needed an industry-experienced partner who understood the science and operational pressures.”
— Alistair Draffan, President
2018 – 2020
Collaboration Beyond Borders
As we became a qualified vendor for Contract Research Organizations (CROs) within and outside of Australia, our reputation for quality grew. However, 2020 brought a challenge that tested the entire scientific community: the COVID-19 pandemic.360biolabs rose to the occasion, becoming the first Australian laboratory to develop and validate SARS-CoV-2 microneutralization assays to support COVID-19 vaccine studies. This pivotal moment underscored our role as a critical link in the global vaccine and infectious diseases network.
2021 – 2022
Advancing Health Globally
Due to high demand, particularly from sponsors advancing into international Phase 2 programs, it became clear that our clients needed seamless support beyond Australia. To meet that need, 360biolabs joined forces with BioAgilytix. This acquisition instantly expanded our global footprint into the United States and Europe with labs in North Carolina, Massachusetts, California and Germany. While our footprint went global, in 2022, we expanded in Australia, opening a Brisbane laboratory to provide real-time sample processing for the state’s thriving clinical trial sector.
“This acquisition represents far more than geographic expansion, it’s a deliberate step in our long-term strategy to build a truly global, science-led bioanalytical partner. As our sponsors advance into larger and more complex international programs, they need seamless support at a global scale. By bringing our teams together, we’ve expanded our reach while strengthening our technical depth and operational resilience. Expansion for us isn’t about size it’s about impact to human health.”
— Angela Luttick, Executive Vice President, Commercial
2023 – 2025
Doubling Down on Excellence
Over the past two years, our journey has been defined by significant expansion and strategic investment in our future. We launched our purpose-built facility in Melbourne, designed to double our footprint and create a state-of-the-art laboratory tailored to advance bioanalytical science.
“We work side by side our clients, using a collaborative and agile approach to method development, always pushing for the highest quality while meeting demanding timelines. That commitment set us apart. As we’ve grown and expanded our capabilities, one thing has never changed: our belief that “every sample counts.” Behind every sample is a crucial data point, and behind every data point is the potential to move a program forward and ultimately improve a patient’s life.”
— Melinda Pryor PhD, Executive Vice President, Scientific Operations
What’s Next? The Future of 360biolabs
360biolabs has experienced strong growth in the last decade, driven by a clear mission to continually expand our laboratories and capabilities so we can deliver truly comprehensive solutions for our clients. Every assay we develop, every method we validate, and every sample we analyse reflects our founding belief that we evolve alongside the science and alongside the partners who trust us with their clinical programs.
Our story has demonstrated the benefits of the Australian Advantage, combining world-class bioanalytical expertise in a favourable regulatory environment, speed, and cost-effectiveness.
The next chapter for 360biolabs is about purposeful expansion. Investing in advanced technologies, deepening scientific specialisation, and strengthening our national footprint to ensure we remain Australia’s most comprehensive bioanalytical laboratory. Our mission remains unchanged: to enable future medicines.
As we mark 10 years of progress, we thank our dedicated scientists, partners, and clients who have shaped this journey.
Interested in conducting a clinical trial in Australia with 360biolabs bioanalytical excellence?